The ink was barely dry on President Trump’s cannabis rescheduling order when the same question started bouncing around boardrooms, Discords, and trader timelines:
Does this mean cannabis can finally uplist to the NYSE or Nasdaq?
Short answer: no.
Longer answer: also no, and maybe stop treating Wall Street like it’s the finish line.
Schedule III moves cannabis to a different column in a federal spreadsheet. It does not legalize the plant. It does not reconcile state markets with federal law. It does not protect operators, consumers, or patients from prohibition.
What it does is change the number next to the word “marijuana.”
That’s it.
The uplisting fantasy
Major U.S. stock exchanges do not operate on vibes, hope, or Twitter threads. They operate on legality.
Cannabis remains illegal under federal law. Schedule III does not change that. Cultivation, distribution, and sale are still prohibited outside narrow federal channels that state-legal operators do not exist within.
So no, this is not a green light for Nasdaq. It is not even a cautious nod.
That does not mean uplisting will never happen. It means anyone pretending it suddenly became simple is guessing, speculating, or selling a story they want to be true.
And here’s the part nobody likes to say out loud.
Even if uplisting were magically unlocked tomorrow, it would not fix the core problem facing cannabis in America.
What actually changed
Schedule III does one very real thing.
It likely kills 280E.
That matters. That is money. That is oxygen.
Operators may finally deduct ordinary business expenses like every other regulated industry. Cash flow improves. Margins stabilize. Some companies survive that otherwise would not have.
That is not nothing.
But it is also not freedom.
It is relief inside a system that still criminalizes the plant and the people who use it.
Wall Street was never the point
Here’s the uncomfortable truth the industry keeps circling without landing on.
Cannabis does not need Wall Street to be legitimate.
Wall Street needed cannabis.
The public market era was sold as validation. What it delivered instead was volatility, crushed valuations, and a transfer of control to people who never cared about weed, culture, or patients in the first place.
Meanwhile, many of the strongest brands in the country stayed private. They built trust, not cap tables. They answered to customers, not quarterly calls. They survived because they focused on product, community, and consistency.
Going public is not a moral victory. It is a financial tool. And sometimes, it is a bad one.
What rescheduling did not touch
Let’s be clear about what Schedule III does not do.
- It does not free anyone from prison.
- It does not stop arrests in prohibition states.
- It does not guarantee medical access for veterans.
- It does not fix banking.
- It does not allow interstate commerce.
- It does not end federal prohibition.
If you consume cannabis in much of this country, you are still breaking federal law.
That has not changed.
So when the conversation jumps straight from rescheduling to stock listings, it feels wildly disconnected from reality.
People are still incarcerated. Patients are still denied access. States remain trapped in regulatory silos. The war on cannabis did not end. It got a better press release.
Why the stock obsession misses the point
There is a quiet distortion happening in cannabis right now.
Policy analysis keeps getting filtered through portfolios.
Justice becomes price action. History becomes timing. Public health becomes a trade.
If your entire analysis of cannabis reform begins and ends with how it moves your stock this week, you are not having the same conversation as the people who have lived under prohibition.
And that gap matters.
Because cannabis did not grow for Wall Street. And the people who paid the price for prohibition did not do it so the plant could chase a ticker symbol.
The real takeaway
Schedule III is not a full breakthrough. It is an admission.
An admission that the federal government can no longer pretend cannabis has no medical value. An admission that decades of policy were wrong. An admission that reality finally forced their hand.
But admissions are not justice. And better PR is not reform.
If rescheduling helps companies breathe, good. If it unlocks research, great. If it lowers prices, even better.
Just do not confuse that with liberation.
High Times note: A cleaner balance sheet is progress. Ending prohibition is the point.
